Remove 2013 Remove FDA Remove Labelling
article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As folks steeped in the world of generic drugs And Hatch-Waxman know, theres a lot that happens before FDA can take action on an ANDA.

FDA 96
article thumbnail

STAT+: Former Sage executives join biotech VC Cure Ventures

STAT

The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Smartphone-powered trial backs J&J’s Invokana for heart failure

pharmaphorum

Updated labelling for Invokana has already been approved to include data showing that it can reduce the risk of hospitalisation for heart failure and diabetic kidney disease in patients with type 2 diabetes, based on the CREDENCE trial. . billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Labelling 105
article thumbnail

Mounjaro interactions to avoid

The Checkup by Singlecare

Drug interactions | Food interactions | Other interactions | Avoiding interactions | When to see a doctor Mounjaro (tirzepatide) is gaining popularity as a treatment for Type 2 diabetes mellitus and off-label for weight management. We do not know if tirzepatide is associated with MTC in humans.

article thumbnail

What is Special about September 24, 2023 for the UDI System?

The FDA Law Blog

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. The compliance dates were first published in 2013, and subsequently updated in various guidance documents and regulations published by FDA.

article thumbnail

Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities

The FDA Law Blog

On October 17, 2022, FDA published the list of CDRH proposed guidances for FY 2023 (see here ). These are documents on the A-list, a list of prioritized documents that FDA intends to publish during FY2023. FDA published draft guidances for these topics in December 2021 ( here and here ).

article thumbnail

What states use Ozempic the most?

The Checkup by Singlecare

Most healthcare providers will prescribe Ozempic off-label or Wegovy only if weight loss can reduce the risk of a more serious health condition. Food and Drug Administration (FDA) recently approved Zepbound , a new version of Mounjaro, for weight loss. It should not be prescribed to patients who want to lose just a few pounds.

Insurance 105